Characteristics | Â | SSc (n = 51) | Controls (n = 22) | |
---|---|---|---|---|
 |  | lcSSc(n = 33) | dcSSc (n = 18) |  |
 |  | 47/4 |  | |
Sex (female/male) | Â | 32/1 | 15/3 | 18/4 |
 |  | 57.3 (14.1) |  | |
Age (years), mean (SD) | Â | 59.3 (14.1) | 55.1 (12) | 44.1 (42.0) |
Duration of disease | Â | 72.5 (1-240) | Â | |
month, range (min-max) | Â | 74.5 (6-240) | 54.5 (1-144) | Â |
Organ involvement (No) | Esophagus | 15 | 3 | Â |
 | Heart | 2 | 1 |  |
 | Kidney | 0 | 0 |  |
 | Pulmonary hypertension | 0 | 0 |  |
 | Pulmonary fibrosis | 0 | 0 |  |
 | Sjögren syndrome | 5 | 9 |  |
ANA Specificity (No) | Anti-topo I | 11 | 13 | Â |
 | Anti-ACA | 10 | 14 |  |
 | Anti-U1 RNP | 3 | 3 |  |
Mean skin score (SD) | Â | 2.8 (3.4) | 11.9 (9.4) | Â |
Steroid treatment | Â | 4 | 5 | Â |